Bilateral anterior uveitis after immunotherapy for malignant melanoma

Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chia-Jui, Chen, Shih-Jen, Hwang, De-Kuang, Liu, Catherine Jui-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169330/
https://www.ncbi.nlm.nih.gov/pubmed/30294532
http://dx.doi.org/10.4103/tjo.tjo_88_17
_version_ 1783360500206141440
author Chang, Chia-Jui
Chen, Shih-Jen
Hwang, De-Kuang
Liu, Catherine Jui-Ling
author_facet Chang, Chia-Jui
Chen, Shih-Jen
Hwang, De-Kuang
Liu, Catherine Jui-Ling
author_sort Chang, Chia-Jui
collection PubMed
description Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior uveitis after immune checkpoint blockade therapy with pembrolizumab and ipilimumab for malignant melanoma. His symptoms and signs improved after topical treatment with corticosteroids. Clinicians should be aware that uveitis can be an immune-related adverse event of immunotherapy.
format Online
Article
Text
id pubmed-6169330
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-61693302018-10-05 Bilateral anterior uveitis after immunotherapy for malignant melanoma Chang, Chia-Jui Chen, Shih-Jen Hwang, De-Kuang Liu, Catherine Jui-Ling Taiwan J Ophthalmol Case Report Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy. Herein, we report the case of a 65-year-old male who suffered bilateral anterior uveitis after immune checkpoint blockade therapy with pembrolizumab and ipilimumab for malignant melanoma. His symptoms and signs improved after topical treatment with corticosteroids. Clinicians should be aware that uveitis can be an immune-related adverse event of immunotherapy. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6169330/ /pubmed/30294532 http://dx.doi.org/10.4103/tjo.tjo_88_17 Text en Copyright: © 2018 Taiwan J Ophthalmol http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Chang, Chia-Jui
Chen, Shih-Jen
Hwang, De-Kuang
Liu, Catherine Jui-Ling
Bilateral anterior uveitis after immunotherapy for malignant melanoma
title Bilateral anterior uveitis after immunotherapy for malignant melanoma
title_full Bilateral anterior uveitis after immunotherapy for malignant melanoma
title_fullStr Bilateral anterior uveitis after immunotherapy for malignant melanoma
title_full_unstemmed Bilateral anterior uveitis after immunotherapy for malignant melanoma
title_short Bilateral anterior uveitis after immunotherapy for malignant melanoma
title_sort bilateral anterior uveitis after immunotherapy for malignant melanoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169330/
https://www.ncbi.nlm.nih.gov/pubmed/30294532
http://dx.doi.org/10.4103/tjo.tjo_88_17
work_keys_str_mv AT changchiajui bilateralanterioruveitisafterimmunotherapyformalignantmelanoma
AT chenshihjen bilateralanterioruveitisafterimmunotherapyformalignantmelanoma
AT hwangdekuang bilateralanterioruveitisafterimmunotherapyformalignantmelanoma
AT liucatherinejuiling bilateralanterioruveitisafterimmunotherapyformalignantmelanoma

Ejemplares similares